Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1999 1
2000 1
2001 1
2002 5
2003 4
2004 3
2005 5
2006 1
2007 1
2008 6
2009 2
2010 1
2011 3
2012 1
2013 2
2014 5
2015 8
2016 11
2017 8
2018 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28129558

67 results

Results by year

Filters applied: . Clear all
Page 1
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. Swords RT, et al. Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Leuk Res. 2016. PMID: 27736729 Clinical Trial.
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. Swords RT, et al. Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. Leuk Res. 2017. PMID: 28575698 No abstract available.
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. Day BW, et al. Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007. Cancer Cell. 2013. PMID: 23410976 Free article.
Tyrosine kinases as targets for cancer therapy.
Krause DS, Van Etten RA. Krause DS, et al. N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389. N Engl J Med. 2005. PMID: 16014887 Free article. Review. No abstract available.
Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D. Caivano A, et al. Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100. Oncotarget. 2017. PMID: 28415715 Free PMC article.
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A. La Rocca F, et al. Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18. Cell Oncol (Dordr). 2017. PMID: 28721629 Free article.
67 results